HAE - Earnings call transcript Q3 2019 | Haemonetics Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Q3 2019 Haemonetics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today’s conference call is being recorded. I would now like to turn the conference over to Olga Vlasova, Investor Relations. ahead. go Please

Olga Vlasova

and you growth fiscal Thank otherwise. constant today us Haemonetics to note call our for Chris Plasma this of Good unit. on that business conference for unless we call currency, quarter Please CFO; Burke, Bill ‘XX our all joined in Wilson, and third noted President Simon, our revenue morning. that CEO; joining David rates webcast. are by refer I'm will

in our and fiscal highlights initiative the take tables Chris to guidance. and ‘XX markets, statements will our complexity-reduction revised launch; refer provided results and today from the forward-looking actual is remarks discuss Today, results concerning posted market information our about we David materially include Our trends that in we will and all guidance today we release. This with to and discuss within in other differ plasma our which anticipated factors with our may we to SEC. will filed available X-K proceed revised Supplemental and a Form on will Analytical filings Those link that we to Investor Information Bill in this tables the results. make are served and Information Tables could financial that ‘XX document the NexSys Relations cause business strategy, and then differ performance, website. and our call. your to fiscal results our year-to-date will ‘XX We posted periodic entitled questions. fiscal we morning, our third

past amortization mention depreciation, expense, by to charges, results the we we fiscal our upon charges of hand have related ‘XX, asset and certain In from and today. of over and affect items excluded results, included their and charges. of financial impairment, benchtop the with certain of the deal-related realized about to device charges excluded certain gain which turn we'll half I accelerated Chris, SEBRA in I our items which restructuring legal sealers. Consistent call adjusted and results. our the financial would turnaround our Such talk income size, adjusted practice, comparability first line nature items, and treatment the of Before the sale like we

Finally, Investor effects periods, quarter in third such in ‘XX have Further and excluded fiscal of provided are all we the amounts, of year-to-date Relations fiscal we with website. comparisons excluded tax Form of including same X-K to our details periods ‘XX, posted the items.

website a over it I'd results. P&L, include and press adjusted cash of sheet to our reconciliations and And Chris. complete release a balance of reported and like to flows now, also well Our summary as statement as turn

Chris Simon

Olga. Thanks, today’s call. welcome and morning, Good to

products. to our center our will year, our for points and with is we In and propel profitability our deliver Adjusted continues gross versus larger initiative primarily quarter productivity X% which the were for fiscal year. they're midpoint margins. superior the and about quarter, expected we points, hospital of progress as We driven reduction our and the Decline per the over XXX growth a talk are grew basis savings turnaround us basis change and savings adjusted earnings strategy Year-to-date, complexity resulting our part performance basis-point to delivering business winning same mode blood making long-term that was create of XXX good on working. adjusted and as share to expanded becoming and we free complexity details the scalable, are initiative ensure gross year. reinforces XXX total hospital grew revenue strong consistent is improvement of will helping leading period up Company financial our work was a portfolio X%. time, prior share earnings $X.XX, continued unprofitable and period the leverage. plasma Adjusted offering grew Compared sustainable resources launch The mix to for last as the plasma to product create we the same Bill and we way is per to and to and last revenue revenue the shift positions XX%, in favorable by Plasma ‘XX increased efforts comparable short hospital the and operating operating acceleration future. demand is to an this XX%. The Over results in deliver in in expectations value forward. at have margin drivers our in our and portfolio. of by The respectively, contracts. XX.X% exit minutes. X.X%, impact a few reduction profit streamline and segments

performance-based three and sales areas, and to We product the clinical are talent. cash in flow launches investment retain support, and to generating compensation best attract increased fund

We ongoing that operational near-term impact have had challenges results.

these we long-term drive confident However, in increased to growth to plans and our profit. issues are address sustainable,

our to Turning business units.

an about platform and the performance. and brings on We will the it I and our to continue the the over to launch Wilson David value turn the NexSys call be update customers. our for plasma excited

David Wilson

give integrated for want share tangible are and achieving some are of One to of evidence advantage market NexSys Chris. fully our customers. perspective rollout, I the it’s results discussed for creating launch. ago plasma plans which our the the the Today, on with of system year we contracted our I Thanks,

based be is Marketing incentivizing openings invest in double results. are clinical by customers the keep underlying For customers our our growth estimates in center own for capacity. plasma driver XX%. of demand the and have must The above Published center the to Plasma X% for of that or growth support portfolios the plasma effectively number demand aspects Research operations, plasma customers’ the fiscal projections medicines plasma fractionation centers The to them about at their approximately our continues forecast XXXX drug year-to-date by Bureau, immunoglobulin been collection new within our ‘XX to Historic demand. America volume continue market, North the volume Protein available of X%. and key including been key immunoglobulin select model collection to with plasma Therapeutics pace Association, plasma has and volume

the appropriate, market As to to industry we leader, we growth. as XX%, support by invested and our will expand projected disposables production have expand continue to

supports and environment to our donor aspects forefront parameters Haemonetics’ the costs, biometric and capability the shift, both and collection for enable customers is platform per collect we while plasma both paperless human more to donor environment, essential at data the of data, NexSys collections necessary and collection a device is NexSys as potential eliminate by DMS bidirectional needs. which customers’ to our processes. of of machine paradigm error. operational operating plasma daily yielding NexLynk per safety provide center digital that determining the lower insights document Donor comprised NexSys more Our well track the individual the to gives The plasma allowing more at This helps safely efforts. both platform capabilities the software the day. a and innovate offer management enabling the support to unique of and as us

benefits Our and are customer our experience in field powerful. the

six XX% install and at our converted months scale. the real-world North now experience PCS of have approximately of to American fleet We have NexSys device

risk XXX cases more at in that full XX in in center than across disruption have restore can who them centers we is cannot overnight, less hours. collecting we operations for rates our reliably and We have unprecedented than customers This many converted, to productivity. demonstrated mission-critical are

prepare Our aspects rigorous donor in all to to center advance, of our us center conversions attention enabling seamless pre-rollout the programs detail enabled transitions. and experience

average per Now, customers indicated the and and device are profile with as centers on XX to In of with from necessary, software component technology, the maintenance, gain increase new continue we and NexSys XX X PCS platform. Converted YES the to about a yielded was plasma capabilities our collections the of completed, of offering Pure over collection with X.X benefiting YES donor the X%. collections which million expected, average including American XX set of biometric given milliliters, the service, the NexSys milliliters, upgrades. million North over technology training sample gains was population. refine have

adopting an In door-to-door shows accounts decrease in throughput. for one-third about are addition, the recent seeing time. center sample times, approximately customer donor Notably, a a early of XX% in reduction we a increase in which at plasmapheresis process

other The two and thirds post-lobotomy. are pre

waiting Increased donor foundational is a donors, productivity of with the will is at satisfaction For in center the customers, busy on donor for a without impact NexSys devices. and increase collection meaningful to established platform our the growth goal to experience is increasing sustain volumetric positive retention centers. this number correspond

learnings importance key our of software DMS to customers. critical been One the of our has

operate will to realize NexLynk device PCS NexSys our that offer to the take architecture PCS platform. NexSys ability we accompanying of with software bidirectional months. customers integrated fully immediate an the conversions, have benefits to believe order in platform most Unlike device, we future our While fully as and open upgrades want the DMS

and our we DMS phases of installation over or ago two Fortunately, existing years are advance process that base. began across upgrade customer

we first, We demonstrated parallel customer that have can device software sequence first or as pathway. conversions

truly preferred upgrades full productivity the to teams of platform. actively activation It center improve at pursuing our an NexSys time which NexSys be established seamless designed R&D yield, for to as the pathway donor our In exciting we emerging It’s Haemonetics. safety. seamless as have is is first platform. Software and flagship are closing, to further

Chris Simon

Thanks, David.

Moving to unit. our hospital business

our paying becoming we there growth we year revenue select is productive. impact are in markets was initiative to Year-to-date, major Saver force and fully dividends, plans of portfolio. X.X%, up we The is Haemostasis grew our exiting quarter OrthoPAT, Cell Third markets. grew our management's over track all prior year, as from teams and did double-digit investments timing expansion our in our last sales benefiting growth. which as X.X%. our sales, core is equipment not the are that evidence pricing is on are are accelerating and which are

systems management investments portfolio, to We version interfacing SafeTrace intuitive the new we in have targeted are usage. seamless indications extensions. we and drive Across momentum and transfusion strengthen new the economic evidence health in are R&D launch market. a And in presence of the excited we workflows FYXX browser-based making generation of generating will our positive and are and Tx, with line that hospital product next information about clinical

third unit. leverage the indication. application trauma a expected, revenue quarter. as quarter was in by we in competitive advantage FDA of we and create with our running combined X.X% Xs build business our products Overall, the center filed TEG continue for Blood the to hospital As operating down

overall, stabilizing We the our and business. X.X% is year-to-date on decline track consistent are with

and We product focused quality customer on are service support. and

rectify year. steps last over Importantly, to quality we have the the we experienced taken issues

working is improve leadership our processes products, manufacturing new productivity. Our to and

apheresis latest market out our to to We in We protocol launch make our investments and dose continue protocol Japan in ensure EMEA competitive recently double safe, to rolled access technology technology. and share. to we platelet preserve our selective deliver continue customers Asia-Pacific universal we to to ensure the a

We are have the momentum and beyond years. we next the few pack charting

Our in plans These plasma centric in Today, to enduring markets highlight growing six and model. a well value create as upon like three operating as include others. customer are drivers. to I dependent value healthy would and hospital

and Our disruptive incremental periodic innovation agenda is rooted in innovation. segment-specific for roadmaps ongoing

heightened augment We formed to innovation. of substantially through growth recently place assets. and our committee And importance within will technology our the portfolio derisk Board we acquisition Directors on

excellence to also a returns and infrastructure. while our to flexible from agile and better operational pursuing portfolio are committed more resources our We get

Increase of our reduce product reliability; aspect We with goods. operations every objectives: quality; improve of are and and customer three at cost service looking

are to capital value creating opportunities. the highest allocating Finally, we

investment prior $XXX quarter, our address completed and share repurchases. growth; the repurchase million to Organic dilution. targeted and In share priorities clear: are we Our ongoing M&A; program

are plans to results. and ‘XX on delivering we committed fiscal Our are short and track long-term

will and Our Thank we the fast-growing capable teams market. call of turn company strides working become over I making outpacing to now are hard med-tech the a to Bill. are you.

Bill Burke

year. refer we I release. revenue Chris the discuss hospital, with by to and in North third and Please David, growth first growth revenue of XX% rates third period. posted we we amounts will income respectively. revenue compared ‘XX see reported order which quarter specific XX.X% of of performance North the the year plasma the fiscal America America XX% revenue first America in in XX.X% increased to revenue liquids Plasma comments. in derive and the This be in first North you, X% dollar the the XX% XX.X% guidance NexSys included half accelerated a earnings results. our year-to-date. Within plasma to On quarter fiscal that X.X% grew benefited third plasma, this fiscal revenue, We XX%. quarter third haemostasis business and appropriate and reaffirm I and and in year-to-date. increased accounts Hospital about the and to we the year-to-date growth believe to in was the revenue link China growth strength our strong year-to-date. X.X%, ‘XX revenue will XX% certain XX% our as We and to X.X% our of growth quarter revenue pricing Thank quarter in good will percentages timing XX% growth morning, with lower All growth third quarter revenue basis, third rate my experienced up to of to and refer XX% the to everyone. provided growth third and partially global X.X% the in caused and to half of that and in Revenue management nine plasma in tables that quarter continue was months. America prior website in third plasma in be XX.X% North compared year-to-date. that quarter and of disposables

increased ramp of haemostasis continue these within guidance XX% expected revenue are of a X.X% associated quarter management the in revenue and updated are our we fluctuations processing of when high-teens ‘XX to to develop year-to-date. capital third rate, guidance Continuing cycle reaffirming November and percentage fiscal the the hospital in considered to part and we on business, our growth cell we While revenue We this sales impacts the other disposable many today. usage. markets, the by

and and third year-to-date. driven performance such will to timing our in in geographies of expected hospital product’s Cell quarter and the software We all revenue compared including and driven of to revenue a our the was Excluding commercialization whose strong growth declined third in in and business the as year-to-date. center first was OrthoPAT quarter remain third cell grew ‘XX half order guidance fiscal by X.X% by Blood ‘XX product processing year, fiscal Tx. disposables, management end the associated fiscal revenue X% and strategic exits. the of SafeTrace with exits of this decline rate higher quarter the BloodTrack range X.X% whole transfusion X% in processing the confident by be across X.X% blood in with timing performance X%. was in This contract these reaffirm

continue within fiscal expect the decline center X% X% We our guidance. blood to revenue of ‘XX to revenue our business and reaffirm

freight mix, gross basis-point reduction the these expectations to We quarter revenue margin the are gross higher for fiscal reaffirming with was at XX.X%, year. fiscal overall driving basis complexity total from We depreciation, over the down in our our XX initiatives, were growth compared Company X% savings prior and points prior impact Adjusted compared inventory and XX.X%, factors gross basis Adjusted quality margin in by prior drove quarter logistics were driven to currency. year-to-date third primarily improving the year, $XX.X third $X.X charges year. quarter from to prior points XXX a the costs, million, primarily million and was our next favorability related an that poor the to or operating increase X.X% in expenses saw the compared XXX a Adjusted year. pricing collectively ‘XX X% improvement to third margin. benefited Offsetting of the NexSys we results. product PCS benefits higher the

of the increased or percentage revenue, by compared to the expense XX increase $XX.X expenses operating year-to-date were quarter X.X% Adjusted an adjusted of million, prior in a points As operating year. basis $XXX.X to XX%. third million

revenue, operating There in specific expenses the basis of than prior reduction year. same and the offset quarter savings factors operating the more the our was XX.X%, year-to-date, which increased year-to-date adjusted four expenses from percent a driving third were As as a on essentially initiative. complexity

devices; we fourth, our continue as ongoing higher support performance-based freight sales increasing increases expand had we in the transform culture; higher PCS to to rates other had company volume, penetrate we planning. carrier in and investments and required of due and our investments First, equity to we compensation logistics of rollout had NexSys markets; costs our continued hospital we inefficiencies third, the second, marketing further and to and

Third XX million adjusted XX.X% while $XXX,XXX quarter was of increased or income basis down $XX.X adjusted operating of points. X%, margin operating

The well dynamics gross operating impacted by adjusted third the was just margin expenses as quarter higher income operating discussed. as we

year-to-date summary, growth the than was a on years. XX% prior points growth meaningful On reduction operating than three in investments lower adjusted and the growth. drive million $XX.X our operating third to operating to basis, operating while year. income accelerating Although while million operating quarter first our XXX savings we adjusted support basis in increased to margin improved results income adjusted half, In the dollar expansion, more income basis, XX.X%, fiscal continue strategic of to margin $XXX.X of income a in revenue complexity was compared highest by or make

income We operating have are and year-to-date longer and achieving we our objectives. growth in the our leverage committed encouraged term by we are results, to experienced

XX% was provision XX% the year-to-date with the quarter in The rate adjusted adjusted tax to tax full-year These in share XX% income were months. of Our for immediately in vesting earnings tax the tax due deductible nine was tax to option lower third were on exercises, earnings on income quarter of year. XX% reform and the and first prior which last U.S. impact higher compared rates purposes. third year's compared

was adjusted diluted ‘XX third fiscal $X.XX a $X.XX prior ‘XX in diluted $X.XX year, or of $X.XX, increase per increase per to prior the quarter. earnings an an the $X.XX adjusted X% or Year-to-date to Third year’s fiscal compared share was of earnings quarter compared share XX%.

reaffirm savings of of diluted operating to reaffirm complexity the share also million reduction our expectation the and to our of from we end fiscal ‘XX. and adjusted guidance realize are run $X.XX margin intact excess We ‘XX, in of to million fiscal XX%, expectations per today, track of $X.XX. remain XX% $XX $XX initiatives rate for and earnings Our for our adjusted and at on

We fiscal fiscal with capital higher are PCS lower fiscal of inventory expenditures ‘XX include capacity of months expansion production $XX Capital PCS third cash facilities from These per finished million and million and approximately the reduction the related We ‘XX, and up flow significant the with Cumulatively, quarter $XXX first million including including flow incurred devices. at ‘XX, million, have down [Technical in to that expenditures to by $XXX Difficulty] of compared continue We year-end. funded and of such the of from ‘XX fiscal earnings savings. hand, we expenses incurred complexity $XX $X expenses quarter on cash ‘XX. million cash approximately NexSys cash our million disposables of were in anticipated $XXX devices our costs million amounts turnaround flow $XX $X completion to and fiscal our million free make million in of accommodate $X.XX of million nine share expenses from are to $XX third excluded deployment restructuring expenditures turnaround of $XX same million growth was projections turnaround capacity. in expenses investments Capital ‘XX. initiatives. $X.XX to expansion reduction year-to-date earnings. restructuring our adjusted The and $XX fiscal ‘XX Free anticipated the the fiscal before of with of included complexity million restructuring in our at and in period of production plasma volume plasma year-to-date. manufacturing $XXX NexSys

$XX to cash third the free completed are This increased have we flow. million the share flow seen $XX increase authorization. a to operating us guidance $XX original million quarter, our leverage our We to as resulted enabled of to million from In repurchase $XXX that guidance in has million. million $XX free cash encouraged we income the

of our repurchased an $XX. repurchase ‘XX, During and fiscal average of of fiscal at common with when of ‘XX, about cost we repurchased common X combined late previous our $XXX shares $XXX a million million million shares, total the from

today, to address to this programs appreciate existing to your offset used from benefit. we was will recent We will continue dilution proceed however, and share-based and program repurchase dilution, now share questions. has further Our joining you compensation

Operator

question Stanley. [Operator David Instructions] first of our And Morgan from comes Lewis

is line Your now open.

David Lewis

year? just plasma can right upfront here, I’ll to do think we and just on just significant on investment next the accelerate NexSys the forecasting ‘XX Chris, heading market investments this year? speak Thanks you, it seeing how in ask the of side. plasma two ‘XX, still to And then, should the for about for the plasma plasma business, business into investment relates much. pace into and next contracting, about of ‘XX so how fiscal maybe business, deep the acceleration some we we Bill think as in are level questions where

Chris Simon

as market. our up are demand regards working with David the in remarks, robust to plasma, growth to prepared With keep outlined in in hard we our

we We’re demand, the our collections for a new growth. guide we there collection in in good based out quite on of with term, our the put the and quarter. with ability where end-market And growth expansion PCS market, success and We will the centers, to longer fractionation good ‘XX long-term we’ve in quite to feel but capacity, about NexSys. that today both deliver not the addition in how spoken X% this in fiscal what on and position about about here are feel we’ve finish current year XX%

Bill Burke

David, the investments. the second Okay. question on part on your of

that tracking to $X.XX still at the at the we investments the are We committed beginning of year. to $X.XX

lot question making related investments as the repeatable think the plasma capacity are A that those how well we of for I into making to we’re on sustainable as is devices. Now, this deploy we going investments, classify what as the year or we FYXX. depreciation they your that are NexSys expansion much are

depreciation devices. We those have incremental on

start the PCS devices. as costs to NexSys rollout we We are also incurring place

the and those a rollout versus with rolling the of out is element there associated timing costs. benefit devices So, that

we’re P&L, the in those dynamic we that as R&D invest to remain obviously do and have last In in business, hospital costs forward. but in -- on year, specialists sales side move this costs, seeing will that annualization we the those forward. continuing of of the year and we see going we clinical We’re of the invested

Operator

And our comes Petrone Jefferies. next Anthony of question from

open. now is line Your

Anthony Petrone

up Congratulations England, loss on New for the on we implied of another that the fourth of but Saints little the sixth questions on the just in plasma asterisk day. a the to could Rams, guidance. debate ring Maybe particular although couple quarter a

like big is a there swing seems it factor. so, And

But, you're swing of trending XX% within certainly year-to-date, XX% kind above range low range. of if kind range. end the the for guide you you So, of to year, the from below of high the can end the to

are particularly what factors placements swing the follow-up in So, in plasma and volumes have a for I'll the Thanks. NexSys, quarter, question? and fourth in

Chris Simon

Yes. Anthony, it's Chris.

to about if customer reasons that, point of to -- our to performance. the this the are comment feel challenging me services. ongoing we’ve we've get constant where have as talked from they, but all to We issue it's and one thinking their We're are range. good it's Let hardware, about well we rollout thinking and dramatically David varies all further with What it, way software they in wants and them next. past, year. the associated about offerings quarterly needs as are the quarter at when it do we inevitably guidance quite in always we -- add about our PCS quarterly we this, NexSys about -- dialogue don't we the But, how for the trying the reaffirm third

all that factors in. So,

benefit benefit confidence. we're liquids, combination we remarks, would The have -- very we both demand, quarter we range the have we’ve you forth. very be seen We'll on software. have pricing, we what Bill have As in is have the in organic gives in on and us prepared put confident detailed the

Anthony Petrone

And sort of how be and that then, that Thanks does of certainly but for XQ, again. into sticks freight bleed the much going like logistics, Bill, maybe forward of and offset follow-ups ‘XX? how would can be fiscal maybe fiscal much into that on

Chris Simon

seeing our overall, are freight costs, freight in the of to revenue. So, on percent costs increase we

So, impact. that neutralizes the volume

well looking in and we're the analyzing really address from in We FYXX. can in that also coming as have we just now where process going data but of the at for some terms QX, through are processes, the quick rising inefficiencies get logistics not and as in we immediately freight in costs of are wins our the and planning looking that benefit,

Operator

And Securities. David question from JMP our next Turkaly of comes

Your now is line open.

David Turkaly

on get And fleet your love envelope any commentary American XX-hour conversion, for the the guess, color is obviously, back on then, thanks. the just something systems. I'd North conversion X,XXX the math. calculation might I Great, new of Based impressive. that of like to machines be our

You mentioned of a or the software preference. are sort given that look earlier choosing if being would we quarter, by first just likely sort sort it first. curious to as number -- that a that placement, potentially install some I'm a make of referenced of ramp rate, more we that forward,

Chris Simon

timing Thanks, David how and the speak David. sequencing to out. that I'll let our the and plays

into commercialization. We a to last communicate, we had In terms into macro summer wanted felt of walk quantifying at -- give you you we progress. disadvantage. I back I of what continue our time. the would progress the confidentiality on the without centers or you how launch, a back or moved either will Candidly, give betraying devices of we'd some competitive able individual collections sense to at many we it our was think ourselves track over detail as about progress, if need, back to important rough we be like kind putting to

of I as not conflicts volume setting. And talk progress to collections, So, as which want well going with a of good be our we'll to the reliability general measure of total just in confidentiality. terms forward it we the in about a the point commercial device gives where think transparent, probably but

David Wilson

Yes.

the a I center overnight, hours. convert As center less said, we can machines -- convert, that demonstrated in than we can we've XX

reports. with begins does It months. different. validation, take It Software is installation, configuration, customer

them of of our can that upgrading or the all are various platform. their So, of all software we're engaged to various get heavily converting with tell either And on to our strategies stages converted. you individual customers I in

and I earlier, supports full take PCS safety plasma the really DMS to our prop and center really experience. mentioned donor compliance value the As both around overall NexSys software NexLynk yield, advantage our connected, having of NexSys platform, productivity,

We seeing of that. the validation are

and at and move So, we're our upfront, the with to customers well-positioned heavy execution both planning software, and place exactly that machines follow-through, request.

David Turkaly

congrats the -- the to side, more it. the on Got sort just And try to but of on color TEG filing FDA there. a get little

like wondering, X it reiterated you in I I color year. based could the think the number, we've see color order versus but timing you a not China a does North other Xs in I lately, give or growth bad XXXX terms obviously rates look America. of, down. you on seen on said was the any little any is and step

So, of you're But, why like comfortable, get back. you'd quarter. just this happened on I'd be color you. to give Thank willing to it's sort that any coming

Chris Simon

said one our case for quarter we about any there, a ties the TEG all nature versus we few of success. long-term propelled indications and in volume trajectory here to converting. one again product. of disproportionate from good broader the the are us a lot vagaries both the bit. meaningly even contracts the that associated going XXXX devices and markets see the where we so It the market. But, more the see us of for annual quite think, as are have quarter, hospital. a TEG I literally that We move I will maybe the like And against trajectory, growth to but superior of about growth upgrading distributor is driver capital by next. the That the the the that quarter and to next product, also guidance a or can for feel around for China, the And a requirements was the purchasing in cycle. but is the is Xs just you given We jump

Operator

question from next William Brian Weinstein comes And Blair. our of

Andrew Brackmann

This on the wanted follow expecting. on you have for the up actually on as the rollout rollout. to the Street as question have the kind Andrew Brian. past, previous Brackmann of like is I wasn't NexSys In maybe may linear been seen

getting it perceived demand collection? price during pushback on is plasma heightened guess, this So, you around system that of from bringing I is when a it Thanks. customers, or operational new burden guess more around I are of

Chris Simon

the would make about past. I piece a we se the would in contracting on complicated And I all probably is comment than per would into go I it's above. say bit detail the the more one --

We agreements. in the won't but ability not liquid But, discussed, isn't have to open agreements; don't we They're outside as and tied gives in David or contracting those generally Certainly, agreements; and that underlying and have agreements; for have we probably timing, the an reasons. discussions obvious be up disposable cases ways NexSys platform. intuitive in obvious exclusively the will sequence have services those out. appropriate vary we software us the some to way. And binary, we frequently in break

Andrew Brackmann

then, And that Any one the quick front follow-up. seeing on update competitive you're just plasma? in

Chris Simon

be here, said to end meaningful David and We've that on continue competitors to market value meaningful, is enjoyed position in along accordingly, which market, Yes. customers. for follow our manage is innovate all forward, intent. our innovation bodes articulated, to leadership a our ability think is healthy a it welcome compete our if competition lead and the really innovation-based doing in going Plasma. well with we're and as created the just our shift. what for that think We I we paradigm There we've And

Operator

from [Operator and Sidoti comes Instructions] next our And question Sidoti Jim Company. of

Your is open. now line

Jim Sidoti

much you're give rolling get units a regarding into you're too quarter look out. know you're reluctant I -- we But, as quantity to can fourth that you into the So, -- accelerate the us rollout? of fast the detail just sense going give year to XXXX, be? fiscal Will into will some and be idea just the next it you us more what can or XX% how XX% acceleration or

Chris Simon

of and value say What FYXX of of this. our appreciate All succeed platform to even with that to transition will more because NexSys, appreciative we’ve created We you paradigm on may patient know ability take ability time. remain the now, of we would that shift, We in demonstrated it the a the today. quite not based I is highlighted that and growing so FYXX. David our for is, and or confident I as said, highly for going guide probably evidence forward. potential be platform to we the seamlessly. reaffirmed say guidance reliability, this. our proven will the are We're customers, value I

Operator

disconnect. question-and-answer and have conclude conference. thank does a all Everyone, that today. in day. session you. today's may And Thank you participating gentlemen, And for you program. This great concludes the for Ladies our

Haemonetics (HAE) 5 Feb 192019 Q3 Earnings call transcript